Coya Therapeutics’ (COYA) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $14.00 price objective on the stock.

Separately, HC Wainwright began coverage on Coya Therapeutics in a research report on Monday, September 16th. They set a “buy” rating and a $18.00 price target on the stock.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $7.21 on Thursday. The stock has a market capitalization of $109.74 million, a P/E ratio of -11.09 and a beta of 0.46. Coya Therapeutics has a one year low of $4.40 and a one year high of $10.69. The firm’s 50 day simple moving average is $7.02 and its two-hundred day simple moving average is $7.04.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. As a group, equities analysts expect that Coya Therapeutics will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics in the 2nd quarter worth approximately $61,000. Renaissance Technologies LLC bought a new position in Coya Therapeutics in the second quarter worth about $101,000. GHP Investment Advisors Inc. purchased a new position in shares of Coya Therapeutics in the 3rd quarter valued at approximately $169,000. Finally, Vanguard Group Inc. boosted its position in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares in the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.